ImmunoPrecise Antibodies Stock (NASDAQ: IPA)

ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AAOI

BTOG

CLLS

DGLY

DOCU

ICON

LGCB

OLMA

RBRK

RDUS

RNAZ

SEPN

SIBN

SNES

ULTA

XPEV

XPOF

Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

benzingaai2023_modern_computer_screen_with_stock_chart_stock__c8dae12f-563b-4c3d-ba96-79a17f4c62e4_0

ImmunoPrecise announced a partnership with a biotechnology giant to develop ADCs and bispecific antibodies for the treatment of cancer.

What&#39;s Going On With ImmunoPrecise Stock Thursday?

Test,Tube,Row.,Concept,Of,Medical,Or,Science,Laboratory,,Liquid

Biotech

Health Care

After-Hours Center

Tech

Immunoprecise shares closed higher on Wednesday after the company announced it developed a new class of GLP-1 therapies.

What&#39;s Going On With ImmunoPrecise Antibodies Stock Wednesday?

ImmunoPrecise Antibodies Ltd. - Common Stock

ImmunoPrecise Antibodies Ltd

iShares Core MSCI Pacific ETF

Infinity PAD

INTERPHARM HOLDINGS INC by Interpharm Holdings, Inc.

Interpharm Holdings Inc

Interparfums Inc

Global X Funds Global X Infrastructure Development ex-U.S. ETF

Amplify Digital Payments ETF

Press Releases

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

AI & Tech Breakout: PRSO, IPA, NEHC, SOAR Lead Today's Innovation Surge – More Movers Inside

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

CGTL

HCTI

KLTO

MTWO

NEHC

PNPNF

PRSO

RSLS

SNYR

SOAR

TSX:TIXT

TSXV:PNPN

HC Wainwright & Co.

Benchmark

Screenshot 2024-04-19 at 5.32.16 PM

General

Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results

Screenshot 2024-04-11 at 5.35.10 PM

ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments

Screenshot 2024-03-08 at 1.21.58 AM

ImmunoPrecise Antibodies (NASDAQ: IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology

Screenshot 2024-02-23 at 12.30.48 AM

The &#34;Hub&#34; Of Biotherapuetic Intelligence – This Company Utilizes Powerful AI

Comments

ImmunoPrecise Antibodies

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell